Edition:
United States

Shanghai Pharmaceuticals Holding Co Ltd (601607.SS)

601607.SS on Shanghai Stock Exchange

24.05CNY
1:59am EST
Change (% chg)

¥-0.35 (-1.43%)
Prev Close
¥24.40
Open
¥24.38
Day's High
¥24.38
Day's Low
¥23.96
Volume
8,380,792
Avg. Vol
14,361,347
52-wk High
¥29.25
52-wk Low
¥18.90

Select another date:

Mon, Dec 11 2017

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its Shanghai-based unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

BRIEF-Shanghai Pharmaceuticals Holding unit to take out loan of $100 mln

* Says co's Hong Kong-based wholly owned unit will take out loan of $100 million (about 664 million yuan) form co's controlling shareholder, with term of 180 days

Shanghai Pharma buys U.S. Cardinal Health's China business for $557 million

Shanghai Pharmaceuticals Holding Co has agreed to buy Cardinal Health Inc's China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide.

UPDATE 3-Shanghai Pharma buys U.S. Cardinal Health's China business for $557 mln

* Cardinal Health put business up for sale due to rule changes

Shanghai Pharma buys U.S. Cardinal Health's China business for $557 mln

Nov 15 State-owned Shanghai Pharmaceuticals Holding Co has agreed to acquire Cardinal Health Inc's China business, one of the nation's largest drug distributors, for $557 million.

BRIEF-Cardinal Health to sell its china business to Shanghai Pharma for $1.2 bln‍​

* Cardinal health signs definitive agreement to sell its china business to Shanghai Pharma

BRIEF-Shanghai Pharmaceuticals' unit‍ signs deal to acquire Cardinal in Malaysia

* Says its unit‍ Century Global signs deal to acquire Cardinal Malaysia for about $557 million

BRIEF-Shanghai Pharmaceuticals Holding Co ‍says unit to buy Cardinal Malaysia for US$557 mln

* ‍Century Global to buy Cardinal Malaysia from Cardinal Cayman for US$557 million Source text for Eikon: Further company coverage:

Select another date: